The purpose of this Phase 3 open-label treatment study is to evaluate the safety and
effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute
withdrawal from any opioid, including methadone and buprenorphine. This study will take place
in a variety of clinical scenarios, both in-clinic and outpatient settings.